Sector Experts

Subscribe to
Streetwise Reports

Ask this Expert

Companies Commented On

Kevin DeGeeter

Ladenburg Thalmann

Image: Kevin DeGeeter

Kevin DeGeeter is a director at Ladenburg Thalmann & Co. Inc. He is responsible for equity research coverage of personalized medicine and medical device companies with market capitalizations between $50 million and $5 billion. His coverage focuses on molecular diagnostics and medical equipment used in oncology, cardiovascular disease and infectious disease, as well as related research markets. Prior to joining Ladenburg Thalmann he was an analyst at Oppenheimer & Co., with responsibility for small-cap molecular diagnostic and biotechnology stocks. He has 10 years of buyside and sellside research experience, including positions with J. P. Morgan, PaineWebber, Natexis Bleichroeder and Manning & Napier Advisors. DeGeeter received a bachelor's degree in economics from Colgate University.




Recent Interviews

Diagnostics and Stem Cells Power Productive Portfolios: Kevin DeGeeter (5/30/13) New medical tests can be moneymakers for small- and mid-cap companies: They save insurers the pain of paying more to treat maladies and save patients from unnecessary treatments. In this interview with The Life Sciences Report, Senior Biotechnology Analyst and Director Kevin DeGeeter of Ladenburg, Thalmann & Co. makes his case for diagnostics companies with compelling ideas in the realms of cancer, cardiovascular and surgical testing. He also has one interesting stem cell idea to share.

Testing, Testing: Analyst Kevin DeGeeter on Five Good Bets in Cancer Diagnostics (11/29/12) Because margins in diagnostics and life sciences tools tend to decline over time, the industry is all about scale. The goal is either to develop novel products or tests with high profit potential, or to acquire them. Another strategy is to develop economies of scale through consolidation. In this interview with The Life Sciences Report, Kevin DeGeeter, senior analyst and director of healthcare research for Ladenburg Thalmann, has singled out five important companies with exciting business models or products.

Recent Quotes

"OPK launched 4KScore in the U.S. as a test for prostate cancer." (4/1/14) OPKO Health Inc. - Kevin DeGeeter, Ladenburg Thalmann More >

"OPK disclosed plans to launch 4Kscore in the U.S. by March 31." (3/25/14) OPKO Health Inc. - Kevin DeGeeter, Ladenburg Thalmann More >

"We expect important OPK catalysts over the next six months." (3/4/14) OPKO Health Inc. - Kevin DeGeeter, Ladenburg Thalmann More >

"MSB represents a stock with high near-term potential that many have overlooked." (2/26/14) Mesoblast Ltd. - Kevin DeGeeter, Ladenburg Thalmann More >

"We would look to accumulate OPK shares prior to the 4Kscore launch." (2/13/14) OPKO Health Inc. - Kevin DeGeeter, Ladenburg Thalmann More >

"Based on the strong phase 2 data we expect MSB to initiate a phase 3 study for its MPCs in H2/14." (1/30/14) Mesoblast Ltd. - Kevin DeGeeter, Ladenburg Thalmann More >

"OPK's rolapitant could become the standard of care." (12/16/13) OPKO Health Inc. - Kevin DeGeeter, Ladenburg Thalmann More >

"MSB disclosed positive, topline results from a phase 2 diabetes study." (12/4/13) Mesoblast Ltd. - Kevin DeGeeter, Ladenburg Thalmann More >

more comments

"We expect MBS to use an abbreviated pathway in Japan." (11/21/13) Mesoblast Ltd. - Kevin DeGeeter, Ladenburg Thalmann More >

"Our new valuation methodology on OPK is due to its maturing pipeline." (11/13/13) OPKO Health Inc. - Kevin DeGeeter, Ladenburg Thalmann More >

"MSB presented early but very intriguing data in a stroke model." (11/11/13) Mesoblast Ltd. - Kevin DeGeeter, Ladenburg Thalmann More >

"We reiterate our Buy rating on MSB." (10/31/13) Mesoblast Ltd. - Kevin DeGeeter, Ladenburg Thalmann More >

"OPK's development of Rayaldy appears to be ahead of our forecast." (8/16/13) OPKO Health Inc. - Kevin DeGeeter, Ladenburg Thalmann More >

"OPK revenues in Q2/13 increased 133%; we reiterate our Buy rating." (8/12/13) OPKO Health Inc. - Kevin DeGeeter, Ladenburg Thalmann More >

"We see value in potential synergies between products in OPK's pipeline." (5/30/13) OPKO Health Inc. - Kevin DeGeeter, Ladenburg Thalmann More >

"NEO has been able to continue to grow the topline nicely and maintain margins of more than 45%." (5/30/13) NeoGenomics Laboratories - The Life Science Report with Kevin DeGeeter More >

"OPK's 4Kscore is approved in Europe and should be approved in the U.S. sometime in 2013." (5/30/13) OPKO Health Inc. - The Life Science Report with Kevin DeGeeter More >

"OPK's prostate test remains a source for potential upside." (3/19/13) OPKO Health Inc. - Kevin DeGeeter, Ladenburg Thalmann More >

"NEO grew test volumes 35.3% in Q4/12, which suggests it continues to gain market share." (2/14/13) NeoGenomics Laboratories - Kevin DeGeeter, Ladenburg Thalmann More >

"Consolidation in molecular testing providers is a potential positive for strong operators such as NEO." (2/5/13) NeoGenomics Laboratories - Kevin DeGeeter, Ladenburg Thalmann More >

"OPK's diagnostic programs could be novel and bring unique value." (11/29/12) OPKO Health Inc. - The Life Sciences Report Interview with Kevin DeGeeter More >

"NGNM has an extremely attractive business model; I'm rating it a Buy." (11/29/12) NeoGenomics Laboratories - The Life Sciences Report Interview with Kevin DeGeeter More >

"NGNM is well positioned to be among the leaders in the market." (11/14/12) NeoGenomics Laboratories - Kevin DeGeeter, Ladenburg Thalmann More >

"Closing of the OURLab urology testing acquisition will be a transformational event for OPK." (11/12/12) OPKO Health Inc. - Kevin DeGeeter, Ladenburg Thalmann More >

"OK's acquisition generates meaningful positive cash flow and will reduce 2013's cash-burn rate." (10/22/12) OPKO Health Inc. - Kevin DeGeeter, Ladenburg Thalmann More >

"OPK's PSA test is a source of significant potential near-term revenue." (10/3/12) OPKO Health Inc. - Kevin DeGeeter, Ladenburg Thalmann More >

"WMany investors may not appreciate the potential operating leverage in OPK's Claros model." (8/10/12) OPKO Health Inc. - Kevin DeGeeter, Ladenburg Thalmann More >

"GTG is on track to meet our forecast for commercial performance." (8/8/12) Genetic Technologies Ltd. - Kevin DeGeeter, Ladenburg Thalmann More >

"NGNM is well positioned to be among the leaders in its market." (7/20/12) NeoGenomics Laboratories - Kevin DeGeeter, Ladenburg Thalmann More >

"OPK's rolapitant has the potential to become standard-of-care." (5/17/12) OPKO Health Inc. - Kevin DeGeeter, Ladenburg Thalmann More >

"GENE launched a pretty interesting test for predicting a woman's nonhereditary risk of breast cancer." (5/10/12) Genetic Technologies Ltd. - The Life Sciences Report Interview with Kevin DeGeeter More >

"Rapid changes in underlying technology have created a pressing need for a company like NGNM to help bridge the gap. (5/10/12) NeoGenomics Laboratories - The Life Sciences Report Interview with Kevin DeGeeter More >

"We believe NGNM's favorable operating dynamics are sustainable." (4/25/12) NeoGenomics Laboratories - Kevin DeGeeter, Ladenburg Thalmann More >

fewer comments


Due to permission requirements, not all quotes are shown.